Cardiol Therapeutics Inc. (CRDL.TO)

CAD 1.58

(3.95%)

Operating Expenses Summary of Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.'s latest annual operating expenses in 2023 was 29.53 Million CAD , down -27.02% from previous year.
Cardiol Therapeutics Inc.'s latest quarterly operating expenses in 2024 Q2 was 7.67 Million CAD , down -7.96% from previous quarter.
Cardiol Therapeutics Inc. reported a annual operating expenses of 41.33 Million CAD in annual operating expenses 2022, up 6.69% from previous year.
Cardiol Therapeutics Inc. reported a annual operating expenses of 38.74 Million CAD in annual operating expenses 2021, up 87.25% from previous year.
Cardiol Therapeutics Inc. reported a quarterly operating expenses of 8.34 Million CAD for 2024 Q1, up 4.8% from previous quarter.
Cardiol Therapeutics Inc. reported a quarterly operating expenses of 7.96 Million CAD for 2023 Q4, up 4.0% from previous quarter.

Annual Operating Expenses Chart of Cardiol Therapeutics Inc. (2023 - 2017)

Historical Annual Operating Expenses of Cardiol Therapeutics Inc. (2023 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2023	29.53 Million CAD	-27.02%
2022	41.33 Million CAD	6.69%
2021	38.74 Million CAD	87.25%
2020	20.69 Million CAD	46.45%
2019	14.12 Million CAD	88.53%
2018	7.49 Million CAD	369.7%
2017	1.59 Million CAD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	7.67 Million CAD	-7.96%
2024 Q1	8.34 Million CAD	4.8%
2023 Q4	7.96 Million CAD	4.0%
2023 FY	29.53 Million CAD	-28.54%
2023 Q3	7.65 Million CAD	21.24%
2023 Q2	6.31 Million CAD	-18.9%
2023 Q1	7.78 Million CAD	-14.39%
2022 Q2	9.23 Million CAD	-5.68%
2022 Q1	9.78 Million CAD	-25.27%
2022 FY	41.33 Million CAD	6.69%
2022 Q4	9.09 Million CAD	-31.2%
2022 Q3	13.22 Million CAD	43.2%
2021 Q1	8.98 Million CAD	-6.64%
2021 Q2	6.5 Million CAD	-27.6%
2021 Q3	10.16 Million CAD	56.31%
2021 Q4	13.09 Million CAD	28.87%
2021 FY	38.74 Million CAD	87.25%
2020 FY	20.69 Million CAD	46.45%
2020 Q4	9.61 Million CAD	118.07%
2020 Q3	4.41 Million CAD	23.07%
2020 Q2	3.58 Million CAD	16.48%
2020 Q1	3.07 Million CAD	-6.51%
2019 Q1	3.49 Million CAD	6.88%
2019 FY	14.12 Million CAD	88.53%
2019 Q2	3.75 Million CAD	7.28%
2019 Q4	3.29 Million CAD	-8.17%
2019 Q3	3.58 Million CAD	-4.52%
2018 Q4	3.27 Million CAD	34.4%
2018 Q1	534.73 Thousand CAD	-6.39%
2018 FY	7.49 Million CAD	369.7%
2018 Q2	1.24 Million CAD	133.69%
2018 Q3	2.43 Million CAD	94.92%
2017 Q4	571.22 Thousand CAD	12.59%
2017 Q2	430.05 Thousand CAD	0.0%
2017 Q3	507.37 Thousand CAD	17.98%
2017 FY	1.59 Million CAD	0.0%

Peer Operating Expenses Comparison of Cardiol Therapeutics Inc.

Name	Operating Expenses	Operating Expenses Difference
Aurora Cannabis Inc.	158.53 Million CAD	81.369%
Avicanna Inc.	14.59 Million CAD	-102.424%
Avant Brands Inc.	5.65 Million CAD	-421.95%
Crescita Therapeutics Inc.	12.32 Million CAD	-139.75%
Knight Therapeutics Inc.	155.54 Million CAD	81.01%
MediPharm Labs Corp.	23.08 Million CAD	-27.961%
OrganiGram Holdings Inc.	277.81 Million CAD	89.368%
Canopy Growth Corporation	308.61 Million CAD	90.429%
Willow Biosciences Inc.	7.55 Million CAD	-291.013%
Auxly Cannabis Group Inc.	40.28 Million CAD	26.674%